The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
MitoRx Therapeutics are developing first-in-class, mitochondrial-targeted sulfide-donor therapies designed to
• restore cellular energy
• drive fat loss
• protect muscle
They recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
The machinery that governs gene expression is being targeted to beat cancer.
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
If the disease is in the lungs, why deliver the drugs everywhere else?
